London Clinic Will Begin Delivering Ketamine-Assisted Therapy for Addiction & Mental Health. Third Location Adds to Two Existing Operatons in Bristol and Oslo. Toronto, Ontario–(Newsfile Corp. – March 17, 2022)…

Brings Over 20 Years of Commercial Biotech Experience to Lead Awakn’s Therapeutics Commercialization Activities in the U.S. TORONTO, CANADA, MARCH 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:…

TORONTO, CANADA, March 09, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that…

Entactogen NCE series enhances the potential to treat a broad range of addictions TORONTO, CANADA, FEBRUARY 17, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…

Professor Morgan, Awakn’s Head of Ketamine-Assisted Therapy for Addiction, named one of the 16 most influential women shaping the future of psychedelics by Insider TORONTO, CANADA, 15 February 2022 – Awakn…

Dr. Sessa Will Discuss the Promise of Psychedelic Medicine in Treating Addiction Toronto, Ontario–(Newsfile Corp. – February 10, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954)…

Novel Entactogen NCE series enhances the potential for improved treatment of addiction TORONTO, CANADA, 26 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching,…

Agreement to explore a partnership for MDMA-Assisted Therapy for treatment of Alcohol Use Disorder in Europe TORONTO, CANADA, 19 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF)…

Primary and secondary endpoints achieved, including 86% abstinence over 6 months post treatment and no serious adverse events. TORONTO, CANADA, 11 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…

Groundbreaking Psychedelic study will investigate Binge Eating Disorder, Compulsive Sexual Behavior, and Internet Gaming Disorder TORONTO, CANADA, 05 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:954) (Awakn), a biotechnology company developing…

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding shares. TORONTO, CANADA, 04 January 2022 – Awakn Life Sciences Corp….

TORONTO, CANADA, 15 DECEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN)  (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat…